Docetaxel

Pancreatic Adenocarcinoma

Bristol-Myers SquibbSmall moleculePhase 2Active

BBB

72/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 58/ 100
Competitive Position: 95/ 100

Competitive context

184 Active assets in the Pancreatic Adenocarcinoma cohort.

Asset / Sponsor	Phase	Rating
FLUOROURACILUM Jonsson Comprehensive Cancer Center	Phase 4	BBB
Xaliplatin Jonsson Comprehensive Cancer Center	Phase 4	BB
Irinotecan Jonsson Comprehensive Cancer Center	Phase 3	BB
Olaparib Lantern Pharma Inc.	Phase 3	BB
Capecitabine Zhejiang University	Phase 4	BB

View all 50 →

Same molecule, other indications

Docetaxel is also rated in:

prostate neoplasmActive

BBB

Indicative · Phase 4

73 / 100

cancer of unknown primary siteDormant

BBB

Indicative · Phase 2

72 / 100

prostate adenocarcinomaActive

BBB

Indicative · Phase 3

72 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.